ArticleMovement disorders clinical practice2025
A Comprehensive Analysis of Meibomian Gland Function, Corneal Sensitivity, and Tear Parameters in Early-Stage Parkinson's Disease.
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDry eye in Parkinson's disease (PD) has been studied, but meibomian gland dysfunction (MGD) has not yet been assessed using meibography, and corneal sensitivity data remain limited.
objectivesThe aims of this study were to analyze ocular surface parameters in newly diagnosed PD patients, evaluate MGD using meibography and corneal sensitivity using esthesiometry, and compare with the control group.
methodsThis cross-sectional clinical study included 44 newly diagnosed PD patients and a control group of 44 age- and gender-matched healthy individuals. Clinical staging of PD patients was performed according to the modified Hoehn-Yahr Scale. Patients with early stages such as stages 1, 1.5, and 2 were included in the study. Ocular surface disease index (OSDI) questionnaire, Schirmer test, tear meniscus height (TMH), noninvasive tear breakup time (NITBUT), meibography staging, degree of conjunctival redness using Keratograph 5 M (Oculus, Wetzlar, Germany), and corneal sensitivity measurements using Cochet-Bonnet esthesiometer (Cochet-Bonnet, Luneau, France) were performed in the patient and control groups.
resultsThe Schirmer test, TMH, NITBUT, and corneal sensitivity results were significantly lower in the PD group than in the control group (P < 0.001, P = 0.028, P < 0.001, and P < 0.001, respectively). Meanwhile, the OSDI score, degree of conjunctival redness, and total meiboscore results were significantly higher in the PD group than in the control group (P < 0.001, P < 0.001, and P < 0.001, respectively).
conclusionsThere were significant differences in meibomian gland morphology, tear parameters, and corneal sensitivity between newly diagnosed treatment-naive PD patients and healthy individuals. These patients should be monitored for early ocular surface damage and MGD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.